VISX TWENTY/TWENTY EXCIMER LASER NEEDS ONE-YEAR FOLLOWUP DATA
This article was originally published in The Gray Sheet
Executive Summary
VISX TWENTY/TWENTY EXCIMER LASER NEEDS ONE-YEAR FOLLOWUP DATA to support approval of the device for phototherapeutic keratectomy, FDA's Ophthalmic Devices Advisory Panel concluded at a March 21 meeting in Bethesda, Maryland. As a condition of approval, the panel stipulated that Visx provide one-year followup data on safety, efficacy and stability. The same condition was specified for approval of Summit Technology's excimer laser, which was reviewed on the same day.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.